Quote:
|
Conclusions: 1. LAP has AV activity superior to that of sorafenib. 2. BEV + LAP may be the first clinically-exploitable AV drug combination. 3. Our functional profiling assay system may be used to individualize AV therapy. 4. High dose, intermittent 'bolus' schedules of LAP to coincide with BEV administration may be clinically advantageous, even in HER2-negative tumors.
|
I still don't know what is meant by "high dose intermittent bolus" of Tykerb. Usual dose, i.e. daily pill? Multiple pills but not every day?
I do remember seeing elsewhere that high dose Tykerb might be used before an infusion of chemo to prime the vasculature or the like.